Leveraging VelocImmuneTM Technologies to Advance Development of Next-Generation Antibody Conjugates

Time: 4:30 pm
day: Day Two

Details:

• Regeneron’s VeclociSuiteTM technologies enable rapid generation of large panels of novel fully human antibodies, bispecific antibodies and humanized mouse models
• Reviewing these and other key technology platforms that provide powerful tools for generating and preclinically evaluating
innovative antibody conjugates spanning diverse disease areas and therapeutic mechanisms of action
• Outlining select examples that include conventional and bispecific antibodies conjugated to cytotoxic and immune-modulating agents

Speakers: